Cue Biopharma, Merck expand Immuno-STAT collaboration

By The Science Advisory Board staff writers

November 19, 2020 -- Cue Biopharma has extended the terms of its research collaboration and license agreement with Merck toward developing new clinical candidates for the treatment of type 1 diabetes and an additional undisclosed autoimmune disease. The research will focus on in vivo Immuno-selective targeting and alteration of T cell (STAT) biologics that are designed for targeted modulation of disease-associated T cells in immune-oncology and autoimmune diseases.

Each biologic of Cue Biopharma's proprietary scaffold contains a peptide-major histocompatibility complex (pMHC) to provide selectivity through interaction with T-cell receptors, and a unique costimulatory signaling molecule to modulate the activity of target T cells. The combination mimics signals delivered by antigen presenting cells to T cells during a natural immune response. This results in highly targeted T-cell modulation.

Under the terms of the extension, Cue Biopharma will receive additional financial research support to further study and develop promising preclinical biologics. The companies entered the initial agreement in November 2017 to develop biologics for the treatment of selected autoimmune diseases.

Proteintech, HebeCell to develop cancer immunotherapies
Proteintech and HebeCell have announced a partnership to develop nanobody-based chimeric antigen receptors for cancer cellular immunotherapy use.
New model could improve vaccine, immunotherapy design
A new model used to predict the outcomes of pathogen detection systems as a function of innate immunity may lead to more effective cancer immunotherapies...
Sumitomo Dainippon commences cancer immunotherapy trial
Sumitomo Dainippon Pharma Oncology has dosed the first patient in its phase II expansion portion of a study evaluating DSP-7888, an investigational immunotherapeutic...
Cartesian begins trial of RNA-based cell therapy for COVID-19
Cartesian Therapeutics has initiated a phase I/II clinical trial for the use of its Descartes-30 lead RNA-engineered mesenchymal stem cell therapy in...

Copyright © 2020

CPhI North America
August 10-12
Philadelphia, Pennsylvania United States
Bioprocessing Summit
August 16-19
Boston, Massachusetts United States
6th Annual CAR-TCR Summit
August 30 - September 2
European Congress of Immunology (ECI) 2021
September 1-4
Belgrade Serbia
Medical Affairs Strategic Summit (MASS)
September 13-15
New Brunswick, New Jersey United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter